We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
+79.3%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$1.15B
AUM Growth
+$59.8M
Cap. Flow
-$271M
Cap. Flow %
-23.61%
Top 10 Hldgs %
64.68%
Holding
57
New
16
Increased
6
Reduced
11
Closed
20

Top Buys

Rank Stock Value
1
SAGE
Sage Therapeutics
SAGE
+$97.9M
2
NXTC icon
NextCure
NXTC
+$47.4M
3
TGTX icon
TG Therapeutics
TGTX
+$41.3M
4
CNST
Constellation Pharmaceuticals, Inc.
CNST
+$32.8M
5
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
+$28.6M

Top Sells

Rank Stock Value
1
ZGNX
Zogenix, Inc.
ZGNX
+$72.3M
2
BOLD
Audentes Therapeutics, Inc
BOLD
+$69.8M
3
ACAD icon
Acadia Pharmaceuticals
ACAD
+$40.9M
4
PEN icon
Penumbra
PEN
+$40.3M
5
NKTR icon
Nektar Therapeutics
NKTR
+$38.7M

Sector Composition

Rank Sector Weight
1 Healthcare 86.47%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OPTN
26
DELISTED
OptiNose
OPTN
$10.9M 0.95%
+78,789
New +$10.2M
YARW
27
Yarrow Bioscience, Inc. Common Stock
YARW
$23.4M
$7.67M 0.67%
459
– –
VRAY
28
DELISTED
ViewRay, Inc.
VRAY
$7.24M 0.63%
+1,715,153
New +$5.54M
DXCM icon
29
DexCom
DXCM
$32.2B
$5.71M 0.5%
104,400
-500,656
-83% -$23.7M
LQDA icon
30
Liquidia Corp
LQDA
$7.48B
$5.46M 0.48%
+1,277,955
New +$5.13M
GNFT
31
DELISTED
Genfit
GNFT
$4.13M 0.36%
207,766
-477,787
-70% -$7.47M
IONS icon
32
Ionis Pharmaceuticals
IONS
$8.6B
$3.93M 0.34%
65,000
-205,000
-76% -$12.2M
BBIO icon
33
BridgeBio Pharma
BBIO
$15.7B
$2.75M 0.24%
+78,400
New +$2.17M
INSM icon
34
Insmed
INSM
$21.4B
$2.33M 0.2%
+97,359
New +$1.98M
CYTK icon
35
Cytokinetics
CYTK
$10.5B
$1.7M 0.15%
+160,073
New +$1.64M
ATRA icon
36
Atara Biotherapeutics
ATRA
$75.5M
$1.15M 0.1%
2,800
-17,200
-86% -$5.93M
AXSM icon
37
Axsome Therapeutics
AXSM
$11.2B
$26K ﹤0.01%
+254
New +$10.3K
ALLK
38
DELISTED
Allakos
ALLK
– –
-125,000
Closed -$9.83M
ASND icon
39
CALL
Ascendis Pharma A/S
ASND
$16B
– –
-400,000
Closed -$38.5M
ASND icon
40
Ascendis Pharma A/S
ASND
$16B
– –
-300,000
Closed -$28.9M
EXEL icon
41
Exelixis
EXEL
$13.3B
– –
-309,700
Closed -$5.48M
IOVA icon
42
CALL
Iovance Biotherapeutics
IOVA
$1.82B
– –
-200,000
Closed -$3.64M
NKTR icon
43
Nektar Therapeutics
NKTR
$2.39B
– –
-141,667
Closed -$38.7M
OPK icon
44
Opko Health
OPK
$985M
– –
-92,140
Closed -$193K
PEN icon
45
Penumbra
PEN
$12.6B
– –
-300,000
Closed -$40.3M
STRM
46
DELISTED
Streamline Health Solutions
STRM
– –
-8,676
Closed -$141K
TVTX icon
47
Travere Therapeutics
TVTX
$5.2B
– –
-1,740,000
Closed -$20.2M
KA
48
DELISTED
Kineta, Inc. Common Stock
KA
– –
-25,000
Closed -$2.96M
SILK
49
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
– –
-301,979
Closed -$9.82M
MRTX
50
CALL
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-175,000
Closed -$13.6M
1
2
3

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Great Point Partners's Q4 2019 Portfolio in Review

As of Q4 2019, Great Point Partners held 57 positions worth $1.15B, up 5.5% from $1.09B the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Great Point Partners withdrew a net $271M in Q4 2019, closing 20 positions and reducing 11 holdings. Its most notable exit was Audentes Therapeutics, Inc, an estimated $69.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 85% a quarter earlier.

Against the trend, Great Point Partners opened a new position in Sage Therapeutics worth $57.5M.

  • Great Point Partners's largest Q4 2019 buy was Sage Therapeutics: 796,057 shares worth $57.5M.
  • Great Point Partners added most to Momenta Pharmaceuticals, Inc. in Q4 2019, an estimated $28.6M increase.
  • Great Point Partners's biggest Q4 2019 reduction was Zogenix, Inc., cutting an estimated $72.3M.
  • Great Point Partners fully exited Audentes Therapeutics, Inc in Q4 2019, selling an estimated $69.8M.
  • Great Point Partners's ten largest holdings make up 65% of its $1.15B portfolio in Q4 2019.
  • Great Point Partners opened 16 new positions and closed 20 in Q4 2019.
  • Great Point Partners's portfolio value rose 5.5% quarter-over-quarter to $1.15B.

Based on Great Point Partners's 13F filing for Q4 2019, filed 14 Feb 2020.